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Abstract
Personalized health care (PHC) or precision medicine is a new medical concept that aids
in treatment decisions for patients by tailoring them to their individual needs. It often
employs genetic testing to select appropriate and optimal therapies (pharmacogenom‐
ics). Although this concept is widely applied in oncology, the field of hypertension is
still in the early stages and “personalization” is currently limited to tailoring antihy‐
pertensive treatment according to age, comorbidities, and ethnicity. Despite the fact that
incomplete/lack of treatment response occurs in 10–30% of hypertensive patients for
angiotensin-converting enzyme (ACE) inhibitors and in 15–25% for β-blockers, major
continental guidelines still recommend the use of antihypertensive agents in a “one-
size-fits-all” approach, neglecting the 1977 postulation of the Joint National Commit‐
tee that “all patients must receive individualized therapy programs.” The arrival of
molecular testing offers new possibilities to differentiate monogenetic from polygenet‐
ic disorders and to identify associations between hypertension and drug response to
corresponding genes. Up to 50% of the variation in blood pressure (BP) is attributable
to genetic factors. Polymorphisms have been identified and studied in genes for BP-
modifying receptors,  such as  ADBR (β-adrenergic  receptors),  and pharmacological
pathways (GNB3, RAAS system). Approximately, one-quarter of the currently analyzed
gene  polymorphisms  demonstrate  significant  pharmacogenetic  effects  (ADD1
Gly460Trp and the insertion/deletion [I/D] polymorphism in intron 16 of the ACE gene).
Several large screening studies are currently ongoing to assess the impact on efficacy of
antihypertensive  medication  of  variants  in  hypertension-susceptibility  genes.  The
GenHAT substudy of the Antihypertensive and Lipid-Lowering Treatment to Prevent
Heart Attack Trial (ALLHAT) assessed the predictive validity of the ACE I/D geno‐
type for coronary heart disease. The Family Blood Pressure Program included 11,079
participants  to  map  genetic  variants  associated  with  hypertension.  In  this  review
chapter, we display the current body of knowledge regarding PHC in the treatment of
hypertension. In particular, we highlight genetic variants associated with hyperten‐
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sion and response/non-response to  antihypertensive  substance classes.  Second,  we
describe technological aspects of PHC and display the most recent example of a PHC
marker  used in  preeclampsia  (PlGF/sFlt-1/PlGF).  We then present  the  results  of  a
guideline review, which included six international guidelines (the European Society of
Cardiology/the  European  Society  of  Hypertension  (ESC/ESH),  the  Joint  National
Committee  (JNC)8,  the  Canadian  Hypertension  Education  Program  (CHEP),  the
National Institute for Health and Care Excellence (NICE) and the American Heart
Association (AHA)/the American College of Cardiology (ACC)/the Centers for Disease
Control and Prevention (CDC) and the American Society of Hypertension (ASH)/the
International Society of Hypertension (ISH)) on recommendations regarding PHC in
arterial  hypertension  and  address  contemporary  governmental  health  agency
perspectives on PHC. Finally, we present the view of physicians on the development of
PHC.
Keywords: personalized health care, arterial hypertension, customer, technologies,
genes
1. Introduction
The history of personalized medicine is as old as humankind. Attempts to identify which
patients are prone to a particular disease and which patients will benefit from a particular
treatment reach back to Hippocrates, who stated: “It is far more important to know what
person the disease has than what disease the person has.”
1.1. The term personalized health care
Personalized health care (PHC) describes attempts to tailor medical treatment to the charac‐
teristics of the individual patient. This creates a setting in which individuals can be allocated
into subpopulations. PHC aims to allocate therapeutic and preventive interventions to that
section of the population that is likely to respond [1]. Adequate treatment may lead to a
significant reduction in disease burden by preventing a number of long-term problems, for
example, caused by untreated hypertension including cerebrovascular disease, renal insuffi‐
ciency, and coronary artery disease [2]. PHC can also reduce the response time to treatment
and visit frequency. Drug intake itself can lead to adverse effects—a burden that is usually
balanced against the beneficial effects of therapy [3]. Adverse events are a secondary source
of costs and they increase the likelihood of therapy withdrawal and the risk of non-compliant
behavior. PHC allows adverse events associated with ineffective treatment to be avoided and
can reduce health-care costs significantly. Table 1 exhibits the conceptual components of PHC.
Figure 1 displays the effects of PHC on the health-care environment.
1.2. Treating arterial hypertension
Hypertension is a major public health problem [4] and is the most common modifiable risk
factor for vascular disease [5]. It affects around 992 million people worldwide [6] and has a
high prevalence in Europe [7]. The response to antihypertensive therapy is very heterogeneous
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and this has driven much interest in the pharmacogenomics, which combines the fields of
pharmacology and genomics to establish how a person’s genetic makeup influences their
response to drugs. In pharmacotherapy, on average only 50% of patients receiving a given
drug will experience the expected therapeutic benefit [8]; the remaining 50% experience either
insufficient effects or no effects at all [9]. In patients with hypertension, the rate of incomplete
or absent responses ranges from 10 to 30% for angiotensin-converting enzyme inhibitors
(ACEIs) and 15–25% for β-blockers reaching 30–70% for statins, and 40–70% for β2-agonists
[10]. Overall, it is assumed that only approximately 30% of patients respond adequately to
antihypertensive drugs [11].
Personalized Healthcare in arterial hypertension
Detailed Assessment Comprehensive Assessment Morphological Assessment Functional Assessment
Genomic Testing Family History Intima-Media Thickness Endothelial Function
Laboratory Testing Heart Rate Variability
Evidence on Gender/Age/Ethnicity Stress Testing
Risk Factors/Scores
Table 1. Overview of components of PHC.
Figure 1. Effects of PHC on the health-care environment (causal loop).
1.3. Guideline recommendations and clinical practice
Individualized treatment approaches for patients with arterial hypertension have been
recommended for several decades [12]. As early as 1977, the Joint National Committee (JNC)
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Reports on the Detection, Evaluation, and Treatment of High Blood Pressure (BP) [13] stated
predictively that “all patients must receive individualized therapy programs.” In reality, this
recommendation was replaced with a standardized advocacy of diuretics [14] and the only
individualized component of contemporary blood pressure treatment remains clustering
patients according to gender [15], race [16], end-organ damage, or comorbidities.
1.4. Genetic factors for blood pressure variability
The completion of the Human Genome Project [17] revolutionized medicine. Advances in the
understanding of the human genome have enabled physicians to pursue optimal preventive
health-care strategies instead of the rather reactive health-care approaches used in the past [18].
For the first time, it conclusively mapped all human genes, including those that may account
for hypertension. Up to 50% of BP variation can be explained by either monogenetic or
polygenetic factors [19]. However, it was disappointing that the influence of single gene
polymorphisms was less than expected (<5%) while the impact of race and sex was consider‐
ably higher [20]. BP differences of <0.5 mmHg are normally associated with a single nucleotide
polymorphism (SNP) [10].
1.5. Demand for better technologies
Parallel with these discoveries, breakthrough technologies came on the market, including the
automated high-throughput sequencer [21], as well as new methodologies allowing less
invasive diagnostics such as liquid biopsy [22]. These technologies were primarily driven by
the need for better diagnostics in the oncology field and made the handling of genomic
information more established and accepted.
1.6. Health economic aspects of PHC
Over the last couple of years, payers, health economists, and policy makers evolved as a new
stakeholder group in the health-care landscape articulating an interest in a more cost-efficient
treatment. Genomic investigation allows not only the early diagnosis of diseases but also the
identification of disease sub-entities. Both components have an impact on the health-care
expenditures. In recent years, other fields of medicine (e.g., neonatal diagnostics) have started
using genetic information for patient management. Due to fairly low costs for antihypertensive
therapy, PHC has been slow in entering this field of medicine. Thus, overall, the use of
individualized treatment approaches in hypertension remains low (at around 7% in the USA
[23]). A McKinsey ranking from 2010 [24] regarding the scientific and economic potential of
companion diagnostics, which was based on expert interviews and other quantitative factors,
yielded low values for antihypertensive assays (<1.7 on a scale from 0 to 2.7 for the economic
potential and 1.1 on a scale from 0.4 to 2.8 for scientific potential), putting them in a “no-go”
area for company investment. Not surprisingly, the analysis showed high values for oncology,
anti-infectives, and autoimmune drugs. However, what is very often forgotten is the fact that
a test, particularly one that is able to show high per-patient savings in a highly prevalent
disease, can be a very attractive opportunity. Thus a test that can prevent or drastically delay
an ischemic cardiac or a cerebral event can be considered as a favorable asset. In addition, PHC
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tests in hypertension are less likely to create microeconomic incentives for prescribing
physicians. This is because the treatment of hypertension is a predominantly conservative
discipline and not associated with costly procedures.
1.7. Pharmacogenetics
In more recent years, the International Haplotype Project contributed to better understanding
of genetic polymorphisms by developing a map locating genes affecting health, disease, and
responses to drugs (HapMap) [25]. However, in 2010 only around 10% of all Food and Drug
Administration (FDA)-approved drugs include pharmacogenomic information in their labels
[26], and a total of 39 FDA-approved drugs demanded genetic testing at that time [27]. By
contrast, another study of 200 top-prescribed drugs showed that pharmacogenetic data were
available for up to 71.3%, although only 24% of all cardiovascular drugs in the 200 top-
prescribed drugs had pharmacogenetic data [28]. Of these, approximately 23 and 18% of
pharmacogenetic data in the cardiovascular and hormone/hormone-modifier classes, respec‐
tively, were related to drug-metabolizing enzyme and drug transporter genes (i.e., pharma‐
cokinetics) [28]. Trials investigating variants in hypertension-susceptibility genes and their
interaction with antihypertensive therapy, for example, GenHat [29], have been initiated as
well as biobanks and registries to assess information about pharmacogenomics of hyperten‐
sion, including the Family Blood Pressure Program [30] and the Pharmacogenetics Knowledge
Base (PharmGKB; https://www.pharmgkb.org/).
The following chapters review various aspects of PHC in arterial hypertension, namely genes
in arterial hypertension, technologies used in PHC, guideline recommendations on PHC, and
physician views on PHC. Finally, a case study of PHC displays the impact of a medical value
assay on the management of preeclampsia.
2. Genes in arterial hypertension
BP is a complex physiological trait that is affected by complex interplays between genetic and
environmental factors. Gene variants may affect BP variability by acting on gene and protein
expression. Thus, the characterization of genes associated with BP may provide not only a
deeper understanding of the cellular processes involved in BP regulation but also how
transcripts mediate genetic and environmental effects.
Many trials have demonstrated a substantial heritability of BP. Adoption, twin, and family
studies document a significant heritable component to BP levels and hypertension [31–33].
Estimates of the heritability of resting systolic and diastolic BPs, based on family studies, are
thought to be generally in the range of 30–60% [34]. A heritable component to salt sensitivity
of BP has been described in black Americans [35]. A large proportion of the phenotypic
variation in BP appears to be inherited as a polygenic trait [36, 37]. A wide variety of ap‐
proaches, such as linkage and candidate gene studies (CGSs) or studies of families with rare
Mendelian high or low BP syndromes, were used for the search for genes associated with BP
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variability [38–42]. Nevertheless, the majority of genetic contribution to BP variation remained
unexplained.
Systolic blood pressure Diastolic blood pressure Hypertension
SNP Chr. Nearest gene SNP Chr. Nearest gene SNP Chr. Nearest gene
rs12046278 1 CASZ1 rs13423988 2 GPR73/ARHGAP25 rs17806132 2 PMS1
rs7571613 2 PMS1 rs13401889 2 MSTN rs305489 3 SYN2
rs448378 3 MDS1 rs9815354 3 ULK4 rs7640747 3 ITGA9
rs2736376 8 MTMR9 rs7016759 8 EFCAB1 rs11775334 8 MSRA
rs1910252 8 EFCAB1 rs11014166 10 CACNB2 rs899364 8 FAM167A/BLK
rs11014166 10 CACNB2 rs11024074 11 PLEKHA7 rs11014166 10 CACNB2
rs1004467 10 CYP17A1 rs2681472 12 ATP2B1 rs2681472 12 ATP2B1
rs381815 11 PLEKHA7 rs3184504 12 SH2B3 rs278126 12 CIT
rs2681492 12 ATP2B1 rs2384550 12 TBX3/TBX5 rs11612893 12 FZD10/PIWIL1
rs3184504 12 SH2B3 rs6495122 15 CSK/ULK3 rs16982520 20 ZNF831/EDN3
SNP, single nucleotide polymorphism; Chr., chromosome.
Table 2. Meta-analysis of CHARGE and Global BPgen of top 10 loci for systolic and diastolic BP and hypertension
(adapted from Levy et al. [43]).
It is conceivable that BP variation in the general population may be a reflection of the sum of
multiple variants with small effects. Thus, very large studies might be needed to identify such
effects. In fact, large-scale genome-wide association studies (GWAS) have identified numerous
gene loci that are associated with BP [43–45]. As an example, the top 10 loci for systolic and
diastolic BP as well as for arterial hypertension derived from the Cohorts for Heart and Aging
Research in Genome Epidemiology (CHARGE) Consortium [46] and the Global BPgen
Consortium [43] are summarized in Table 2.
The study of the genetic background of an individual may be helpful to analyze the intrinsic
and extrinsic susceptibility for a disease as well as the effects of the disease on the individual.
The potential of such a personalized, particularly genome-based approach to arterial hyper‐
tension is summarized in Figure 2. Obviously, the treatment of chronic conditions would not
start before the earliest possible time of point detection. In many cases, it will only start with
substantial delays after this time point and many chronic conditions, including hypertension,
will only be detected when acute or chronic end-organ damage becomes clinically overt
resulting in deleterious consequences for the patient [47]. In these conditions, genome-based
information across the continuum of health and disease may complement and improve the
current approach by early identification of individuals at risk for a disease and, at the same
time, enabling early preventive and/or therapeutic interventions [48, 49].
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Figure 2. Opportunities for PHC in hypertension.
2.1. Potential application of genomics in risk stratification in arterial hypertension
Associations between genes and hypertension identified by GWAS or CGS are limited by small
effect sizes limiting the ability of individual genes to predict the development of hypertension.
This limitation can be overcome by constructing genetic risk scores that combine the effects of
multiple genetic variants into a single variable. A potential application of genetic risk scores
can be the early identification of patients at risk for developing hypertension. Published
examples include a genetic risk score derived from data from the British Genetics in Hyper‐
tension (BRIGHT) study and a genetic risk prediction model derived from the Wellcome Trust
Case Control Consortium (WTCCC) study [50–52]. Unfortunately, genetic risk scores for
hypertension only have a very limited predictive power [51] and therefore add little additional
information compared to non-genetic risk prediction models.
2.2. Potential application of genomics in therapy guidance
More promising applications of genetic testing are expected from the field of pharmacoge‐
nomics (i.e., the study of genetic predisposition to drug response). It is estimated that 1.56
billion adults worldwide will be diagnosed with arterial hypertension by 2025 [6]. Being a
chronic condition, hypertension usually requires lifelong therapy. However, despite a wide
variety of available antihypertensive drugs, BP is controlled in only approximately 50% of
patients. Moreover, therapeutic strategies in the general population have not been as effective
as expected from clinical trial results [53]. These data indicate that the optimal approach to
antihypertensive therapy has not yet been established and that further improvements in
patient care and treatment efficacy need to be achieved.
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Drug class  Gene  Population  Drug  Data
source 
Reference 
Diuretics YEATS4 White-/African-
Americans/Others
Hydrochloro-thizide GWAS,
CGS
 [56, 57]
PRKCA Swedish/Norwegian, Finnish GWAS  [58]
NEDDL4 Swedish/Norwegian, White-/ African-
Americans/Others, White-/African-
Americans/ Hispanics
CGS  [59, 60]
FGF5
SH2B3
EBF1
White-/African- Americans/Others CGS  [61]
CLIC5
RUNX2
Finnish GWAS  [62]
TET2
CSMD1
Italian GWAS  [63]
ACE
Inhibitors
/
Angiotensin
II Receptor
Blockers
AGT Chinese, Indian Enalapril/ Inidapril,
Benazepril
CGS  [64–66]
AGTR1
NR3C2
Chinese Enalapril CGS  [67]
ABCC9
YIPF1
Japanese Not specified GWAS  [68]
FUT4 White-/African- Americans Candesartan GWAS  [69]
GPR83
SCNN1G
CYP11B2
Not specified CGS  [70]
STK39 Finnish Losartan GWAS  [71]
CAMK1D Italian GWAS  [72]
GRK4 Japanese Losartan, Candesartan,
Telmisartan
GCS  [73–75]
Beta-Blockers ADRB1 White-/African- Americans
Hispanics
Metoprolol CGS  [76]
FGF5
CHIC2
MOV11
HFE
White-/African-
Americans/Others
Atenolol CGS  [61]
GNB3 Italian CGS  [77]
GRK4 White-/African- Americans/Hispanics CGS  [78]
LPL
PPARA
Europe, Africa, Asia CGS  [79]
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Drug class  Gene  Population  Drug  Data
source 
Reference 
TNFRSF11B
APOB
ADRA1A
CACNB2
LIPC
CASR
Calcium
Channel
Blockers
PICALM
TANC2
NUMA1
APCDD1
Japanese Not specified GWAS  [68]
KCNMB1 White-/African-
Americans/Hispanics
Verapamil CGS  [80]
CACNA1C White-/African-
Americans/Hispanics
CGS  [81]
PLCD3 Swedish/Norwegian Diltiazem CGS  [82]
GWAS, genome-wide association study; CGS, candidate-gene study.
Table 3. Pharmacogenetics/genomics studies in arterial hypertension by drug class.
In this respect, pharmacogenomic approaches have the potential to lead to the development
of diagnostic tools for predicting the most effective therapeutic approach to hypertension. In
fact, an increasing number of studies have revealed and continue to reveal genetic variants
that are associated with response or non-response to antihypertensive drug classes such as
diuretics, β-blockers, calcium channel blockers (CCBs), ACE inhibitors, and angiotensin II
receptor blockers (Table 3). While parameters obtained from anthropometric, biochemical, or
technical examinations are helpful for the adequate selection of drug classes that will provide
optimal end-organ protection, they are of limited value for predicting the individual response
to antihypertensive therapy [54, 55]. Unfortunately, despite promising data, information on
interactions between gene variants and antihypertensive drug efficacy is not yet part of the
routine evaluation of hypertensive patients. This may be due to confounding factors (e.g.,
environmental or epigenetic factors). Their effect is far less well understood and more research
is needed to further clarify the interplay between genes, environment, and response to
antihypertensive therapy.
3. Technologies for PHC in essential hypertension
BP has a significant genetic component, but only a minority of cases is attributed to genetic
variants identified to date [83]. There is a general belief, however, that by further understand‐
ing these interactions, there is high potential in PHC for the prevention and treatment of
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essential hypertension. While most studies focus on the types of analytes that could be relevant,
such as nucleic acids and proteins, here we investigate the technologies currently in use and
those with the biggest potential for PHC in hypertension.
3.1. Real-time quantitative PCR and digital PCR
Polymerase chain reaction (PCR) has become an indispensable tool in biomedical research.
Real-time quantitative PCR (qPCR) allows measurement of the amplification of a targeted
DNA molecule in real time based on fluorescence [84]. The resulting PCR curve is used to
define the exponential phase of the reaction, which is a prerequisite for the accurate calculation
of the initial copy number at the beginning of the reaction [84, 85]. One study developed a
screening test based on six multiple SNP loci associated with essential hypertension and was
able to demonstrate significant correlation between one SNP and patients with hypertension
[86].
Although qPCR is still the technology of choice, the latest PCR technology—the so-called
digital PCR (dPCR)—now offers measurement of nucleic acids with generally superior
precision, sensitivity, and reproducibility over qPCR [87, 88]. In dPCR, the sample is separated
into a large number of partitions, allowing for simultaneous template amplification separately
in each partition. The latest development of dPCR technology employs thousands to millions
of reaction partitions, thus providing a scalable multiplexing environment [89]. The advan‐
tages in terms of sensitivity and reliability demonstrate the potential of dPCR for molecular
diagnostics, for example, in the cell-free DNA fraction of blood plasma, but the technology has
not yet been introduced into mainstream clinical practice, and hence no reference was found
for the use of dPCR with regard to genetic testing for hypertension.
3.2. Next-generation sequencing (NGS)
In the past decade, there has been extraordinary progress in our ability to sequence the human
genome and the price of sequencing an average human genome has dropped from approxi‐
mately US$10 million to below US$1000 [90, 91]. Most sequencing technologies use similar
protocols with common methods for template preparation (building and amplifying a library
of nucleic acids), nucleic acid sequencing using library fragments as template from which a
new complementary DNA fragment is synthesized, and imaging and data analysis [92]. The
actual sequencing occurs through a cycle of washing and flooding the fragments with known
nucleotides in a sequential order, and digital recording of incorporated nucleotides [92]. Raw
sequencing data then undergo several layers of data analysis to rebuild the sequence from a
multitude of DNA fragments, after which the compiled sequence can be analyzed [93].
Targeted sequencing, such as whole-exome sequencing, allows us to investigate the coding
part of the genome, which represents only about 1.5% of the genetic code. The exome can be
sequenced at a much lower cost compared with the whole genome, and with deeper coverage
(>100× vs. 30–40× coverage), which increases accuracy [94]. Technological advances in high-
throughput genomic sequencing enabling genome-wide association studies and whole-exome
sequencing are expected to bring greater insights into the genetic causes of essential hyper‐
tension and will eventually bring those technologies into clinical practice [79]. Numerous
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companies are working on the development of high-throughput genomic technologies in order
to make genomics information universally available.
Examples include Genia, with its nanopore technology for single molecule sequencing, and
Illumina Inc., which has developed large-scale whole-genome sequencing on the HiSeq X
Series and Thermo Scientific (http://www.pacb.com/products-and-services/; https://
www.thermofisher.com/ch/en/home.html) [95, 96].
To fully reveal the potential of NGS, it is important to consider multiple sources of genetic
information, such as inheritance and association studies, and bioinformatics. For example, the
application of next-generation linkage and association methods to hypertension demonstrated
that OSBPL10—a disease-susceptibility gene for dyslipidemia—might also influence systolic
BP [97]. A novel statistical approach to detect genetic associations between a trait and SNP
regions across the entire genome (whole-genome sliding-window-based optimal weighted
approach) revealed three highly susceptible windows across chromosome 3 for diastolic BP
and identified 10 of 48,176 windows as the most promising for influencing both diastolic and
systolic BP [98]. A recent analysis of functional differences in hypertension pharmacogenes
was conducted by investigating human genomic variation using data from the 1000 genomes
project, coupled with a functional prediction analysis [79]. Results indicated significant
interpopulation differences depending on geographical origin, giving insights into interindi‐
vidual differences in antihypertensive drug response and suggesting that rare variants mainly
determine the functionality of hypertension pharmacogenes [79]. However, there have been
few of these studies and more research based on NGS technologies is necessary to further
understand hypertension pharmacogenomics and to fully leverage them for PHC [79].
3.3. Bioinformatics
The above examples underline the fundamental role played in PHC of the ability to process
and analyze huge volumes of data, such as electronic medical records, in vivo imaging,
genomics, and other “-omic” technologies [94, 99]. Millions of genetic polymorphisms are
identified with NGS technology; but in order to find an association between a polymorphism
and a phenotype, a large number of statistical tests have to be performed and then require
correction for multiple testing [100]. A methodology was recently proposed for unified analysis
of NGS data. A pipelined series of statistical and bioinformatics methods was used to analyze
associations between genetic polymorphisms and a disease phenotype, using hypertension as
the example, and to identify statistically significant pathways of genes that may play a role in
the disease [100].
3.4. Epigenomics
Rather than just being affected by variations in the coding genome, epigenetic mechanisms,
including microRNAs, histone modification, and methylation, are increasingly seen to play a
role in the development of hypertension [101]. Non-coding areas of the human genome, which
make up almost 99% of it, were long regarded as “junk DNA” [102]. In contrast, the Encyclo‐
pedia of DNA Elements (ENCODE) project has shown that non-coding DNA is a critical
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element of gene function regulation across cell, tissue, and organ types [103, 104]. The
ENCODE project systematically mapped regions of transcription, transcription factor associ‐
ation, chromatin structure, and histone modification, which enabled them to assign biochem‐
ical functions for 80% of the genome [103]. Regulatory elements, such as transcription-factor-
binding sites, histone modification, chromatin structure, and DNA methylation, are highly
cell-type specific. Those non-coding regions are extensively transcribed into non-coding
RNAs, such as microRNAs and long-non-coding RNAs (lncRNA), with various functions
including the influence of the pathophysiology of hypertension [102]. For example, micro‐
RNAs seem to be associated with hypertension via sympathetic nerve activity, ion transporters
in the kidney, endothelial function, vascular smooth muscle phenotype transformation, and
communication between cells [102]. In another study, expression levels of microRNAs
implicated in vascular smooth muscle cell phenotypic modulation were assessed in patients
with hypertension and healthy controls. Changes in vascular smooth muscle cells play a critical
role in the pathophysiology of arterial remodeling in essential hypertension. Levels of hsa-
miR-143, hsa-miR-145, and hsa-miR-133a were downregulated, and hsa-miR-21 and hsa-miR-1
upregulated in peripheral blood mononuclear cells of patients with hypertension compared
with normotensive subjects [105]. There also seems to be potential for clinical use of non-coding
RNAs to identify or treat patients with cardiovascular diseases [106, 107]. As non-coding RNAs
are a relatively new field of research for hypertension, the number of supporting studies is
small, and further research is needed [107].
3.5. Other “omic” studies and technologies
Despite the leading role of genomics, other new “omics” technologies have been developed
that allow us to bridge between genotype and phenotype [92].
3.5.1. Transcriptomics and differential gene expression
Transcriptomic approaches allow us to study the complete set of RNA transcripts, for example,
through microarray or RNA sequencing. Microarray chips can hold tens of thousands of genes
and can be used to compare gene expression levels in certain disease states [108, 109]. However,
our literature review did not reveal any transcriptome studies addressing PHC in essential
hypertension.
3.5.2. Proteomics
Proteomics gives a snapshot of the proteins present at a given time in a cell or an organism
and might help to reveal novel diagnostic and therapeutic approaches in hypertension. A study
aiming to identify urinary proteins involved in the pathogenesis of hypertension and salt
sensitivity revealed different uromodulin protein levels in individuals with hypertension
versus healthy individuals [110]. Patients with higher levels of uromodulin were homozygotes
for specific UMOD gene variants and displayed a decreased level of salt excretion [110].
Another study assessing the correlation between hypertension with γ-glutamyltransferase
(GGT) and alanine aminotransferase (ALT) levels in a Chinese population revealed that
elevated GGT was associated with hypertension but not ALT [111].
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3.5.3. Metabolomics
Metabolomics studies the metabolites resulting from biochemical degradation processes and
allows conclusions to be drawn on the prevalence of such processes. Several studies high‐
lighted distinctions in the metabolic footprint of patients with hypertension and hence the
potential in its analysis (e.g., through gas chromatography-mass spectrometry and liquid
chromatography-mass spectrometry) [112–114]. One study pointed out that the metabolic
perturbation associated with alcohol abuse may contribute to the development of hyperten‐
sion, probably by a shift in the ratio of the oxidized:reduced forms of nicotinamide adenine
dinucleotide (NADH:NAD+) [112]. Other results suggest that disorders in amino acid metab‐
olism might play an important role in the pathogenesis of juvenile hypertension and circulating
levels of uridine adenosine tetraphosphate are strongly associated with the disease [113, 115].
In another study, sex-steroid pattern was significantly associated with the risk of incident
hypertension [116]. However, more clarity about the different metabolic influences is needed
to translate these findings into clinical practice.
3.6. Importance of mobile technologies
With the omnipresence of new mobile technologies and connected devices, patient self-
monitoring is becoming an increasingly important and promising topic across various
diseases. Despite a large number of mobile apps and devices designed to track general health
and well-being and also BP specifically [117], formal clinical research on such self-monitoring
devices still seems to be limited. Some initial studies focused on patient education in patient-
centered hypertension care [118, 119]. The FDA has cleared some mobile apps for BP and
cardiac monitoring (e.g., the Withings BP Monitor) [120]. Initial studies dealing with patients’
self-monitoring conclude that in order to motivate patients to self-manage their hypertension,
engage with their devices, and communicate through them with health-care providers, it is
crucial that the technology is both flexible and secure [119].
In the following chapter, we compare the content of important international guidelines
regarding PHC in hypertension.
4. Guidelines on PHC in arterial hypertension
4.1. Status quo and guidance in hypertension on personalized medicine: hypertension
guideline perspectives
In this section, we review the content of six international hypertension guidelines regarding
evidence and recommendations on how to execute PHC in the management of high blood
pressure. While the majority of guidelines still emphasize the importance of comprehensive
PHC, only little evidence is displayed on detailed PHC. The guidelines reviewed here are
summarized in Table 4.
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Table 4. Summary of hypertension treatment guidelines.
4.1.1. European Society of Cardiology/European Society of Hypertension
The European Society of Cardiology/European Society of Hypertension (ESC/ESH) guidelines
[121] categorize patients with hypertension according to their BP, medical history, physical
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examination, and laboratory parameters. The ESC/ESH guideline recommends that physicians
detect causes of secondary hypertension, record cardiovascular risk factors, and identify other
cardiovascular diseases. It further advises the evaluation of familial (genetic) predisposition
to hypertension and cardiovascular disease and alludes to 29 SNPs that are associated with
systolic and/or diastolic BP and could be useful contributors to risk scores for organ damage.
Methodologies to detect asymptomatic organ damage in the individual patient are described.
The focus for the heart is on left ventricular hypertrophy; for the vessels, it is on arterial stiffness
and carotid plaque load; for kidney function, on glomerular filtration rate and the existence of
established renal parenchymatous disease on proteinuria. For the brain, the guidelines refer
to silent infarctions, white matter hyperintensities, and microbleeds.
In general, the ESC/ESH guideline concludes that the main benefits of antihypertensive
treatment are due to lowering of BP per se and are largely independent of the drugs
employed. Thus, all drug classes are suitable for the initiation and maintenance of antihy‐
pertensive treatment, either as monotherapy or in combination. The guideline discusses the
hypotheses behind BP recommendations (i.e., the “lower the better” vs. J-shaped curve
theories) and suggests that targeted BP will have to be revisited with additional data
concerning associated organ damage and evaluating different end points (left ventricular
hypertrophy, new-onset microalbuminuria, renal failure, cardiovascular events, etc.). Despite
this uncertainty, the ESC/ESH guideline recommends continued monitoring for asympto‐
matic organ damage. It suggests therapy stratification of antihypertensive drugs for specific
conditions and organ damage types (e.g., with some organ damage certain hypertension
medications are discouraged because of contraindications, while others are recommended,
as they show a greater effectiveness). Monitoring of end-organ damage with (bio)markers
(e.g., serum creatinine level, electrocardiograph, echocardiograph, ankle-brachial index, etc.)
to detect regression with treatment, progression of hypertension-dependent abnormalities,
as well as the appearance of conditions requiring additional therapeutic interventions (such
as arrhythmias, myocardial ischemia, stenotic plaques, and heart failure) is valued in the
ESC/ESH guidelines. Further detail is given on the combinatory possibilities of the drug
classes.
4.1.2. US Eighth Joint National Committee
The US Eighth Joint National Committee (JNC8) guideline [122] presents an evidence-
based approach for the management of hypertension in adults to recommend treatment
thresholds, goals, and medications. JNC8 stratifies its blood-pressure-lowering therapy
recommendations based on age, ethnicity (black vs. non-black), diabetes, and chronic kidney
disease (CKD).
JNC8 gives eight recommendations based on systematic review of the literature. A ninth
recommendation was developed by the panel members based on expert opinion to aid
physicians in implementing JNC8. It includes an algorithm summarizing recommendations
1–8 and advice on combining antihypertensive drugs. JNC8 acknowledges that recommen‐
dation 9 has not been validated with respect to achieving improved patient outcomes and there
will likely be no supporting evidence from well-designed randomized controlled trials.
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The JNC8 dosing regimen proposes three strategies:
• Start one drug, titrate to maximum dose, and then add a second drug.
• Start one drug and then add a second drug before achieving maximum dose of the initial
drug.
• Begin with two drugs at the same time, either as two separate pills or as a single pill
combination.
If BP goals are not achieved, then JNC8 urges that second and third drugs are added from the
list. Continuous monitoring of BP is advised to adjust the treatment regimen until target BP is
reached. The combination of an ACEi and angiotensin receptor blocker should not be used. If
an antihypertensive drug is not effective in a specific situation or has an adverse effect, it can
be replaced.
4.1.3. Canadian Hypertension Education Program guideline
The Canadian Hypertension Education Program (CHEP) treatment guidelines [123] provide
recommendations for the indication of drug therapy, therapy goals, and detailed patient
categorization according to their organ damage or comorbidities. For individuals with diastolic
and/or systolic hypertension, no rigid specification is provided for initial therapy. The
physician can chose from β-blocker, thiazide/thiazide-like diuretic, long-acting calcium
channel blocker (CCB), or ACEi/ARB taking into consideration patient age (β-blocker only in
patients aged <60 years) and ethnicity (ACEi in non-black patients).
In isolated hypertension, β-blockers are no longer part of first-line therapy if patients are aged
≥60 years.
In general, the CHEP guideline recommends global vascular protection therapy for adults with
hypertension without compelling indications for specific agents, including statin therapy in
hypertensive patients with ≥3 cardiovascular risk factors and acetylsalicylic acid therapy in
hypertensive patients aged ≥50 years.
Additional hypertension treatment categories are ischemic heart disease (coronary artery
disease or a recent myocardial infarction), heart failure, stroke (acute and non-acute manage‐
ment), left ventricular hypertrophy, non-diabetic CKD, renovascular disease, and diabetes
mellitus. The specific and detailed BP targets and pharmacological recommendations speci‐
fying initial therapy, second-line therapy, and notes and/or cautions for hypertension are
summarized.
4.1.4. UK National Institute for Health and Care Excellence hypertension guideline
The UK National Institute for Health and Care Excellence (NICE) hypertension guideline
(http://www.nice.org.uk/guidance/cg127) uses patient age as the starting point for their
recommendations, with treatment escalation in a stepwise fashion if BP is not adequately
controlled. If the patient is aged <55 years, step 1 antihypertensive treatment is an ACEi or a
low-cost ARB. In patients aged ≥55 and black people of African or Caribbean family origin of
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any age, NICE recommends a CCB. A thiazide-like diuretic (chlorthalidone, indapamide) can
be selected instead of a CCB if the patients present with edema, intolerance, heart failure, or a
high risk of heart failure.
In step 2, NICE recommends the addition of a CCB to the ACEi or ARB. Alternatively, a
thiazide-like diuretic can be used. In step 3, the combination of ACEi (ARB), CCB, and thiazide-
like diuretic should be used. Resistant hypertension is treated at step 4 by adding diuretics
(low-dose spironolactone, higher-dose thiazide-like diuretic) or a β-blocker or an α-blocker to
the treatment regimen.
NICE recommends that patients aged ≥80 years should receive the same antihypertensive
regimen as people aged >55, taking into account any comorbidities. Patients with isolated
systolic hypertension (systolic BP ≥160 mmHg) should be treated with the same regimen as
those with both raised systolic and diastolic BP. β-Blockers are not preferred for initial therapy
in hypertension, but could be considered in younger patients with evidence of increased
sympathetic drive, intolerance, or contraindication to ACEi and ARB, or for women of child-
bearing potential. If β-blockers are required, then a CCB rather than a thiazide-like diuretic
should be added to reduce the risk of developing diabetes.
BP targets and therapy recommendations for hypertensive patients with diabetes and/or CKD
are not given in the NICE hypertension guideline but appear separately in the NICE guidelines
for type 2 diabetes (NG28; http://www.nice.org.uk/guidance/ng28) and CKD (CG182; chronic-
kidney-disease-in-adults-assessment-and-management-35109809343205). Since publication of
the hypertension guidelines in 2011, there has been an evidence update (https://
www.nice.org.uk/guidance/cg127/evidence/evidence-update-248584429).
In brief, current NICE treatment recommendations for patients with diabetes (http://
www.nice.org.uk/guidance/ng28) comprise first-line treatment with an ACEi or an ARB. If the
patient is of African or Caribbean family origin, an ACEi/ARB should be combined with a
diuretic or a CCB. Second and third steps could be a CCB and/or a diuretic. BP targets are
140/80 mmHg (or 130/80 mmHg if there is kidney, eye, or cerebrovascular damage). Patients
with CKD (albumin:creatinine ratio (ACR) ≥30 mg/mmol) and hypertension should be started
on an ACEi/ARB. Patients with CKD and an ACR <30 mg/mmol and no diabetes should follow
NICE hypertension guideline recommendations (http://www.nice.org.uk/guidance/cg182).
Patients with diabetes and an ACR ≥3 mg/mmol or an ACR ≥70 mg/mmol (irrespective of
hypertension or cardiovascular disease) should also be treated with an ACEi/ARB. In patients
with CKD, target systolic BP should be <140 mmHg and diastolic <90 mmHg (unless they also
have diabetes, see above).
4.1.5. American Heart Association/American College of Cardiology/Centers for Disease Control and
Prevention treatment algorithm
The AHA, American College of Cardiology, and CDC hypertension management algorithm
recommends stratifying treatment according to hypertension stages [124]. Patients with stage
1 hypertension should start with lifestyle modification and treatment with a thiazide diuretic
should be considered. Patients with stage 2 hypertension should immediately start a thiazide
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with either an ACEi or ARB or a CCB. Alternatively, an ACEi and CCB combination could also
be used. If BP cannot be controlled, they recommend a thiazide for most patients or an ACEi,
ARB, or a CCB, or a combination. The next treatment step involves using the highest tolerated
dose or adding another antihypertensive.
The AHA/ACC/CDC algorithm recommends different medications depending on the medical
conditions associated with hypertension as follows:
• Coronary artery disease/post-myocardial infarction: β-blockers, ACEi.
• Systolic heart failure: ACEi or ARB, β-blockers, aldosterone receptor blocker, thiazide.
• Diastolic heart failure: ACEi or ARB, β-blockers, thiazide.
• Diabetes: ACEi or ARB, thiazide, β-blockers, CCB.
• Kidney disease: ACEi or ARB.
• Stroke or transient ischemic attack: thiazide, ACEi.
4.1.6. American Society of Hypertension/International Society of Hypertension clinical practice
guidelines
In the American Society of Hypertension and International Society of Hypertension clinical
practice guidelines, the BP targets are defined according to age and comorbidities [125]. The
target is 140/90 mmHg in the general hypertensive population. In older patients (aged >80
years), the goal is <150/90 mmHg unless these patients have CKD or diabetes, in which case
<140/90 mmHg can be considered. With most patients requiring more than one drug, the
increase of the dose and/or adding a new drug to achieve BP control is required. If the untreated
BP is ≥20/10 mmHg above the target BP, treatment should be started with two drugs simulta‐
neously. The choice of drug is dependent on age, ethnicity/race, and other clinical character‐
istics and comorbid conditions (e.g., diabetes, coronary artery disease, etc.) of the patient.
4.2. Government health agencies’ perspectives on personalized medicine
The European Health Research Directorate of the European Commission defined PHC as a
medical model using molecular profiling for tailoring the right therapeutic strategy for the
right person at the right time, and/or to determine the predisposition to disease and/or to
deliver timely and targeted prevention with fewer side effects. In support of the 2020 vision
for PHC in Europe, the Health Research Directorate of the European Commission started with
a series of four preparatory workshops (http://ec.europa.eu/research/health/pdf/towards-
personalised-medicine-leaflet_en.pdf; http://ec.europa.eu/research/health/index.cfm?pg=pol‐
icy&policyname=personalised, PerMed: http://www.permed2020.eu/) on personalized
medicine covering
• The role of “-omics” technologies for personalized medicine (http://ec.europa.eu/research/
health/pdf/summary-report-omics-for-personalised-medicine-workshop_en.pdf).
• Stratification biomarkers (http://ec.europa.eu/research/health/pdf/biomarkers-for-patient-
stratification_en.pdf).
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• Clinical trials and regulatory aspects.
• Opportunities and challenges for European health care (http://ec.europa.eu/research/
health/pdf/13th-european-health-forum-workshop-report_en.pdf).
This was followed by a conference entitled “European Perspectives in Personalized Medicine”
in 2011, acknowledging the huge potential for PHC and the multitude of challenges (http://
ec.europa.eu/research/health/pdf/personalised-medicine-conference-report_en.pdf). In 2013,
the Commission developed a staff working document on “-omics” technologies in PHC (http://
ec.europa.eu/research/health/pdf/2013-10_personalised_medicine_en.pdf). In 2014, an
additional workshop for Regulatory Aspects and Early Dialogue EHFG Forum 4 “Personalised
Medicine 2020” – October 2, 2014, Bad Hofgastein, Austria (http://www.permed2020.eu/
_media/2_EMA_02-10-14_Ehmann.pdf), was held.
As part of the Horizon 2020 program, a call for a proposal has been issued for “Coordinating
personalized medicine research” (http://ec.europa.eu/research/participants/portal/
desktop/en/opportunities/h2020/topics/2449-sc1-hco-05-2016.html). Thus, the European
Commission attributes great importance to the topic of PHC in general.
Expectations regarding potential benefits for patients, clinicians, and health-care systems are
as follows:
• Ability to make better-informed medical decisions,
• Higher probability of desired outcomes owing to better-targeted therapies,
• Reduced probability of adverse reactions to medicines,
• Focus on the prevention and prediction of disease rather than on reaction to it,
• Earlier disease intervention than has been possible in the past, and
• Improved health-care cost containment.
4.3. Assessment of guideline content
Although some therapy guidance is provided by the guidelines, the method of selection for
antihypertensive therapy is largely empirical [126] and an individual cardiovascular and renal
event risk assessment is yet not possible. In the various guidelines, different approaches have
been taken to stratify patients and integrate BP with either age and ethnicity or other risk
factors. Some guidelines (e.g., NICE) focused primarily on the age and ethnicity most likely
associated with differences in plasma renin activity, while others provide specific recommen‐
dations to integrate different asymptomatic organ damage, metabolic conditions, and cardio‐
vascular and renal comorbidities to establish an individual patient regimen (e.g., CHEP 2015).
This approach is based on the finding that BP reduction is not considered to be the only
mechanism acting to reduce cardiovascular risk, as BP-independent, probably class-specific
effects seem to contribute to the effects of risk reduction with BP-lowering drugs. In a recent
meta-analysis, the evidence of risk reduction for congestive heart disease and heart failure,
and particularly mortality, was found with some drug classes only [127].
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There are efforts to understand the molecular underpinnings of BP regulation. The hope is that
this will improve the prediction of cardiovascular susceptibility and thus could in the future
offer insight into personalized hypertension treatment. As hypertension is a difficult pheno‐
type to access, owing to its variability and susceptibility to other environmental factors and
physiological pathways, another approach could be to search for predictors of antihyperten‐
sive drug responses. If robust predictors of BP response are available, therapy stratification
will be feasible, which could facilitate treatment success.
The available data on genetic markers have been promising in terms of defining genetic
determinants of response to antihypertensive drugs. However, no studies to date have been
sufficiently powered with an effect size large enough to allow genetic markers of antihyper‐
tensive drug responses to be included in the guidelines to inform individualized antihyper‐
tensive treatment decisions. Despite a lack of pharmacogenomics for personalized
antihypertension treatment-guided approaches, Clinical Pharmacogenetics Implementation
Consortium guidelines [128] are available for other cardiovascular drugs (i.e., clopidogrel
[129], warfarin [130], and simvastatin [131]).
To overcome the challenges (small sample sizes in available studies with well-characterized
BP responses and genetic data, replication of genomic signals in independent cohorts,
identification of the biological basis for the genetic association, etc.), the International Con‐
sortium for Antihypertensive Pharmacogenomics Studies was formed in 2012. In addition, the
US President Barack Obama has announced a research initiative that aims to accelerate
progress toward a new era of precision medicine ([132], www.whitehouse.gov/precisionme‐
dicine) and the National Institutes of Health and other partners are implementing this vision
(http://www.nih.gov/precision-medicine-initiative-cohort-program).
5. PHC from a physician’s perspective
Despite advances in research and technologies, the PHC concept is still new for a number of
physicians and it remains unclear how quickly the adoption of PHC into routine practice will
occur.
5.1. Warfarin and statins: a field study on genetic testing
There is wide variation in inter-individual responses to anticoagulants, such as clopidogrel,
as well as to statin therapy with underlying genetic differences assumed to be responsible [133,
134]. In fact, of patients with an acute myocardial infarction treated with clopidogrel, those
carrying CYP2C19 loss-of-function alleles had a higher rate of subsequent cardiovascular
events than non-carriers of that allele [135]. The FDA even published a black-box warning
regarding clopidogrel administration, as 2–14% of the population are poor CYP2C19 metab‐
olizers and hence require alternative clopidogrel dosing in order to effectively prevent clotting,
heart attacks, and strokes [136].
Also for the target molecule of statins, 3-hydroxy-3-methylglutaryl-coenzyme A reductase, it
is known that, compared with individual homozygous for the major allele of one of the SNPs,
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individuals with a single copy of the minor allele had up to 22% less reduction in total
cholesterol levels [133].
Genetic screening to guide selection of anticoagulation and lipid-lowering therapy has been
limited to date, because solid clinical data to support its use are not yet available [133, 137,
138]. However, it is believed that the formal integration of genetic testing to optimize warfarin
dosage would reduce over- or under-coagulation of patients. In the US alone, optimal
coagulation has been estimated to translate into an annual reduction of 85,000 serious bleeding
events and 17,000 strokes, leading to a reduction in health-care spending of about $1.1 billion
[139]. In order to investigate the current use and evolution of genetic testing in clinical practice,
interviews with cardiologists in the USA and Germany have recently been conducted.
In a substudy of a recently published analysis [140], we interviewed 39 cardiologists in private
practices, community hospitals, and academic centers in the USA and Germany about their
use of genetic testing for diagnosis and treatment, and treatment guidance. Physicians were
initially asked about how frequently they order genetic (genotyping) tests for cardiovascular
risk factors in patients with heart failure: (i) before prescribing warfarin or clopidogrel and (ii)
before prescribing statin drugs or hydralazine. They were also asked (iii) how frequently they
order genetic tests to diagnose or assess the risk of long QT syndrome and various cardio‐
myopathies or to monitor transplant rejection in heart-transplant patients. In conclusion, the
cardiologists were asked (iv) how they expect the use of personalized medicine tests to change
in the area of heart failure and hypertension. These interviews were conducted by three
neutral, interview-experienced researchers employed by Enterprise Analysis Corporation
(EAC; Stamford, CT, USA), all of whom had strong diagnostic knowledge (one MD, one PhD,
and one BS, MBA).
The results of our interviews are summarized in Table 5 and Figure 3. Only one US cardiologist
routinely ordered genotyping tests to determine patient response to clopidogrel or warfarin.
The majority of interviewees indicated that they never or rarely ordered these tests in cases of
non-response to treatment, with numbers being close to equal in the USA and Germany.
Functional thrombocyte tests were ordered as they were reimbursed. In the case of statins,
only one cardiologist in the USA and two in Germany ordered genetic tests frequently for all
patients to assess responsiveness to statin drugs or for inheritance of familial hypercholester‐
olemia. About 10% of interviewees ordered these tests occasionally but more than 80% never
or rarely ordered these types of tests. Limited clinical benefit, cost, and reimbursement were
mentioned as the main reasons for not using these tests. Although patients with
cardiomyopathies, such as long QT syndrome, and transplant patients, were rare compared
with anticoagulation patients, physicians seem to be aware of the genetic tests that have been
developed for those conditions. Fifteen percent of the physicians mentioned that they ordered
these genetic tests occasionally when they see such a case, but 44% said that they never ordered
these tests. Physicians in private practice often indicated that they referred their patients to an
academic center for specialized evaluation.
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never rarely occasionally frequently all patients total
Warfarin / Plavix
Germany 12 (60%) 7
(35%)
1
(5%)
0
(0%)
0
(0%)
20
(100%)
USA 10
(53%)
7
(37%)
1
(5%)
0
(0%)
1
(5%)
19
(100%)
Total 22
(56%)
14
(36%)
2
(5%)
0
(0%)
1
(3%)
39
(100%)
Statins
Germany 10
(50%)
6
(30%)
2
(10%)
1
(5%)
1
(5%)
20
(100%)
USA 10
(53%)
6
(32%)
2
(10%)
0
(0%)
1
(5%)
19
(100%)
Total 20
(51%)
12
(31%)
4
(10%)
1
(3%)
2
(5%)
39
(100%)
Cardiomyopathies / long QT
Germany 9
(45%)
4
(20%)
3
(15%)
2
(10%)
2
(10%)
20
(100%)
USA 8
(42%)
6
(32%)
3
(16%)
2
(10%)
0
(0%)
19
(100%)
Total 17
(44%)
10
(26%)
6
(15%)
4
(10%)
2
(5%)
39
(100%)
Table 5. Physician responses concerning the use of genetic testing for warfarin/clopidogrel prescription, statin
prescription, and in cardiomyopathies such as long QT syndrome.
Figure 3. Physicians’ responses concerning the use of genetic tests in cardiology.
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Despite the fact that currently most cardiologists barely use PHC tests, most believe that the
use of such tests will increase over the next decade. In the USA, 89% anticipate growth in the
use of these tests, with 37% expecting a slight, 47% a moderate, and 5% a substantial growth.
In Germany, 85% of physicians predict an increased usage of personalized medicine in
cardiology, with 20% expecting a substantial, 60% a moderate, and 5% a slight growth. Only
15% of the German cardiologists and 11% of the US cardiologists do not anticipate any change
in the use of these tests (see Table 6).
Country Expected change, No. of responses (%)
Substantial Moderate Slight No change
Germany (n=20) 4
(20%)
12
(60%)
1
(5%)
3
(15%)
USA (n=19) 1
(5%)
9
(47%)
7
(37%)
2
(11%)
Total (n=39) 5
(13%)
21
(54%)
8
(21%)
5
(13%)
Table 6. Expected change in the use of personalized medicine in cardiology.
Despite the fact that the concept of personalized medicine has been discussed in cardiology
for over a decade, our study has confirmed that there is still no regular use of genetic tests for
pharmacogenomic-guided treatment in cardiovascular disease [139]. Although cardiologists
are known to order general in vitro diagnostic (IVD) tests in 60% of their consultations with
the results of these tests influencing diagnosis or treatment decisions in 70% of cases [140], the
use of genetic testing is still rare in routine cardiology. Our study has shown that only one to
three cardiologists out of 39 ordered genetic tests on a regular basis before prescribing
anticoagulation or statins. For long QT syndrome and other rare cardiomyopathies, physicians
indicated more frequent use of genetic testing, with 15% of cardiologists using them occasion‐
ally.
One reason for the limited use of genetic testing for pharmacogenomics in cardiology seems
to be a lack of sufficient clinical evidence. Physicians often indicate that there is no adequate
benefit to be gained from these tests, which has been mentioned in earlier studies [139]. Even
though newer studies have demonstrated the value of genetic testing (e.g., identifying
CYP2C19*2 carriers for antiplatelet treatment with prasugrel rather than with clopidogrel to
reduce high on-treatment platelet reactivity after percutaneous coronary intervention [141]),
larger clinical utility studies might be needed. Another reason stated by the physicians is the
cost of these tests or the lack of reimbursement. Both reasons highlight little awareness of the
value of genetic testing in terms of economic benefits, which would equal clinical utility and
cost-effectiveness [142]. This indicates that more studies are needed to generate clinical
evidence and proof of economic value for genetic testing in patients with cardiovascular
diseases.
Relevance of Personalized Health Care in Patients with Arterial Hypertension: Where are we now?
http://dx.doi.org/10.5772/63558
159
To showcase a successful example of how PHC is used in a sub-entity of HT, the next chapter
focuses on the development of the sFlt-1/PlGF ratio, used to guide treatment decisions in
patients with preeclampsia. Despite being a secondary form of hypertension, its prevalence is
associated with the existence of chronic hypertension in women. While in the general popu‐
lation the risk of preeclampsia is 3–5%, around 17–25% of women with chronic hypertension
develop superimposed preeclampsia [143].
6. PHC in preeclampsia
6.1. Hypertension in pregnancy
Hypertension is the most common complication of pregnancy [144]. Although many pregnant
women with high BP have healthy babies, hypertension during pregnancy can be dangerous
for both mother and fetus. Hypertensive disorders of pregnancy can be classified as follows:
(a) chronic hypertension (high BP that either precedes pregnancy, is diagnosed within the first
20 weeks of pregnancy, or does not resolve by the 12-week postpartum checkup), (b) gesta‐
tional hypertension (transient hypertension of pregnancy or chronic hypertension identified
in the latter half of pregnancy), (c) preeclampsia-eclampsia, or (d) preeclampsia superimposed
on chronic hypertension [144]. Effects of high BP range from mild to very severe, with serious
cases causing maternal and fetal harm. Preeclampsia and eclampsia, in particular, can be life-
threatening for mother and baby.
6.2. What is preeclampsia?
Preeclampsia is a heterogeneous, multi-organ disorder, which affects 3–5% of pregnancies
worldwide and is a leading cause of maternal death [145–148]. It is associated with placental
dysfunction and can result in adverse outcomes for mother and child. Maternal adverse
outcomes include eclampsia (seizures), HELLP syndrome (hemolysis, elevated liver enzymes,
low platelets), early delivery, placental abruption, renal failure, and death [149–151]. Adverse
outcomes for the child include intrauterine growth restriction (IUGR), intraventricular
hemorrhage, necrotizing enterocolitis, and perinatal death.
The clinical features of preeclampsia are often variable and non-specific. Hypertension is often
present, and is associated with convulsions and other severe cerebral manifestations, but it is
not easily differentiated from gestational hypertension or undiagnosed pre-existing chronic
hypertension. Other signs include headache, proteinuria, visual disturbances, abdominal pain,
edema, sudden weight gain, and vomiting. It is difficult to predict which women who present
with these signs and symptoms during pregnancy will develop preeclampsia. There has been
an unmet medical need to improve current predictive tools in order to better tailor the
provision of specialized management and care to those women who require it.
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6.3. Management of preeclampsia
Currently, there is no cure for preeclampsia, other than delivery of the baby. Available
pharmacological interventions are limited and are generally aimed at treating the complica‐
tions of the syndrome. Such treatments include anticonvulsive medication (magnesium sulfate
[152]) and antihypertensive medications (e.g., labetalol), and the use of corticosteroids to
promote fetal lung maturation ahead of preterm delivery. Clinical experience suggests that
early detection, monitoring, and supportive care are important to improve maternal and fetal
outcomes in this progressive syndrome, by allowing expeditious decision making and referral
to specialist perinatal care centers [153–155]. This requires a reliable model of preeclampsia
prediction in order to appropriately tailor management plans.
6.4. Clinical benefits of preeclampsia prediction: tailoring health care
The use of a clinical measurement (a biomarker) for the prediction of preeclampsia in women
with signs of preeclampsia could facilitate PHC, and ensure that the right patients are
identified for monitoring, for referral to specialist perinatal centers (if required), and to receive
appropriate interventions. Furthermore, the ability to accurately rule out a diagnosis of
preeclampsia could help prevent unnecessary hospitalization and the emotional stress for
patients and their families that this entails. Targeted monitoring and management could also
provide economic benefits for health-care providers, by reducing the level of monitoring
required for those women unlikely to develop the syndrome. Advances in the understanding
of preeclampsia pathogenesis have enabled the identification of potential biomarkers.
6.5. Pathology of preeclampsia
Historically, preeclampsia was defined by the new onset of hypertension and proteinuria
during pregnancy. However, the definition of preeclampsia has recently been revised to
include women with new-onset hypertension without new-onset proteinuria, provided that
there are other new-onset manifestations (e.g., IUGR or maternal renal, hepatic, or neurologic
dysfunction) [156]. In fact, preeclampsia is part of a wider spectrum of conditions, which
involve placental dysfunction, decreased perfusion of the placenta, and inflammation (Figure
4).
In preeclampsia, incomplete remodeling of maternal spiral arteries can lead to intermittent
placental hypoperfusion and oxidative stress, which in turn leads to an exaggerated maternal
inflammatory response [157]. Immune factors (e.g., AT1-AA), oxidative stress, natural killer
cell abnormalities, and other factors may cause placental dysfunction, leading to the release of
anti-angiogenic factors, such as soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin
(sENG). Conversely, circulating maternal serum concentrations of pro-angiogenic placental
growth factor (PlGF) are decreased (relative to normotensive pregnancies) [157]. This angio‐
genic imbalance is thought to cause vasoconstriction and generalized endothelial dysfunction,
which may lead to preeclampsia and fetal growth restriction [158–160]. PlGF has been
investigated as a potential diagnostic and predictive biomarker for preeclampsia [161–163].
The ratio of circulating maternal serum levels of sFlt-1 and PlGF has also been proposed as an
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indicator of preeclampsia; a high sFlt-1/PlGF ratio is associated with an increased risk of
preeclampsia [164–170], and the ratio is elevated in pregnant women 4–5 weeks before the
clinical onset of preeclampsia [166]. There has been evidence to suggest that the sFlt-1/PlGF
ratio (which reflects the in situ balance of an anti-angiogenic factor and a pro-angiogenic factor)
may be a better indicator of preeclampsia than either sFlt-1 or PlGF alone [171].
Figure 4. Pathophysiological features of preeclampsia (adapted from Wang A, Rana S, Karumanchi SA. Preeclampsia:
the role of angiogenic factors in its pathogenesis. Physiology [Bethesda]. 2009;24:147–158).
6.6. Measurement of sFlt-1, PlGF, and the sFlt-1/PlGF ratio
There are a variety of commercially available tests for PlGF, which include the Elecsys® PlGF
immunoassay (cobas e platform; Roche Diagnostics, Mannheim, Germany, Table 7 [172]),
Triage® PlGF test (Alere International, Waltham, MA) [173], DELFIA® Xpress PlGF 1-2-3 test
(Perkin Elmer, Waltham, MA) [162, 163], and the BRAHMS PlGF KryptorTM (Thermo Fisher
Scientific, Waltham, MA) [174]. There are two sFlt-1 assays available: the Elecsys®sFlt-1 (cobas
e platform; Roche Diagnostics) and the BRAHMS sFlt-1 KryptorTM (Thermo Fisher Scientific)
[175]). These are automated assays that use maternal serum.
Elecsys® sFlt-1 Elecsys® PlGF
Assay time 18 min 18 min
Sample material Serum Serum
Sample volume 20 µL 50 µL
Detection limit Approx. 6 pg/ml < 2 pg/ml
Measuring range 10–85 000 pg/ml 3–10 000 pg/ml
Imprecision < 5% < 5%
Table 7. Product characteristics of the Elecsys® sFlt-1 and PlGF assays [172, 175].
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The sFlt-1/PlGF ratio can be calculated using the Roche Elecsys® test or the BRAHMS Kryp‐
torTM assays. It is important to note that the testing methods from different companies are not
interchangeable, and the cutoff levels established with a one-assay ratio are not applicable to
the other assays.
6.7. PlGF and the sFlt-1/PlGF for preeclampsia diagnosis
An Alere Triage® PlGF level of <36 pg/mL supports a diagnosis of preeclampsia [173]. In a
method comparison study the Elecsys® immunoassay sFlt-1/PlGF ratio showed improved
diagnostic utility over the Triage® PlGF assay with improved specificity as a diagnostic aid of
preeclampsia [176].
For the Elecsys® sFlt-1/PlGF ratio, the reference median values during an uneventful preg‐
nancy have been published (Figure 5). The analysis of elevated Elecsys® sFlt-1/PlGF ratios in
women with preeclampsia has been used to establish recommended cutoff levels for pree‐
clampsia diagnosis by gestational age [177]. For the early gestational phase (week 20 + 0 days
to week 33 + 6 days), women with an sFlt-1/PlGF ratio of ≤33 had the lowest likelihood of a
positive preeclampsia diagnosis (sensitivity/specificity of the test: 95/94%), and women with
a ratio of ≥85 had the highest likelihood of a positive preeclampsia diagnosis (sensitivity/
specificity: 88/99.5%). For the late gestational phase (week 34 to delivery), a cutoff of ≤33 to
rule out diagnosis and a cutoff of ≥110 to rule in diagnosis has been recommended (sensitivity/
specificity of 89.6/73.1% and 58.2/95.5%, respectively) [172, 175]. The Elecsys® sFlt-1/PlGF ratio
is CE-IVD (Conformité Européenne–In Vitro Diagnostics) approved for use as an aid in the
diagnosis of preeclampsia in conjunction with other diagnostic and clinical information.
Figure 5. Median values of the Elecsys® sFlt-1/PlGF ratio in uneventful pregnancies [177].
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The BRAHMS KryptorTM sFlt-1/PlGF ratio was assessed for preeclampsia diagnostic utility in
a recent small study (n = 39 women who developed preeclampsia including n = 30 women with
late-onset preeclampsia; 76 controls). To diagnose preeclampsia (rule in preeclampsia), a
BRAHMS KryptorTM sFlt-1/PlGF ratio of >110 had a 67.7% specificity (late-onset preeclampsia),
compared with the Roche Elecsys® sFlt-1/PlGF ratio showing 85.5% specificity [178].
6.8. The sFlt-1/PlGF ratio and preeclampsia prediction
To date, the BRAHMS sFlt-1/PlGF ratio has been assessed only for the diagnosis of preeclamp‐
sia [174, 178]. By contrast, the Elecsys® sFlt-1/PlGF ratio has been validated for both the
diagnosis and the prediction of preeclampsia [172, 175]; it is the predictive role of the biomarker
that is anticipated to guide PHC for preeclampsia, and so the results of studies examining the
Elecsys® sFlt-1/PlGF ratio for preeclampsia prediction are discussed subsequently.
The Prediction of Short-Term Outcome in Pregnant Women with Suspected Preeclampsia
Study (PROGNOSIS) was a large, non-interventional, multicenter study, designed to derive
and validate a cutoff-based prediction model for the short-term prediction of the absence or
the presence of preeclampsia using the sFlt-1/PlGF ratio [171]. In this study, 1050 women with
singleton pregnancies between 24 + 0 and 36 + 6 weeks of gestation, and one or more symptoms
of preeclampsia (but no confirmed diagnosis), were enrolled and split into two cohorts. Data
from the first cohort of 500 women (development cohort) were used to develop a model and
identify the optimum sFlt-1/PlGF cutoff level of 38, which was independent of gestational age
(Table 8). The second cohort (validation cohort, n = 550) was used to validate this proposed
optimum level.
Development Cohort Validation Cohort
Preeclampsia within 1 week, % (95% CI)
Negative predictive value (rule out) 98.9 (97.3–99.7) 99.3 (97.9–99.9)
Sensitivity 88.2 (72.5–96.7) 80.0 (51.9–95.7)
Specificity 80.0 (76.1–83.6) 78.3 (74.6–81.7)
Preeclampsia within 4 weeks, % (95% CI)
Positive predictive value (rule in) 40.7 (31.9–49.9) 36.7 (28.4–45.7)
Sensitivity 74.6 (62.5–84.5) 66.2 (54.0–77.0)
Specificity 83.1 (79.3–86.5) 83.1 (79.4–86.3)
Calculations of sensitivity were defined based on participants who developed preeclampsia within 1 or 4 weeks.
Calculations of specificity were defined based on participants who did not develop preeclampsia within 1 or 4 weeks.
CI denotes confidence interval.
Table 8. Validation of a sFlt-1/PlGF ratio cutoff of 38 for rule out and rule in in preeclampsia ([171]; From New
England Journal of Medicine, Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, Olovsson M,
Brennecke SP, Stepan H, Allegranza D, Dilba P, Schoedl M, Hund M, Verlohren S, Predictive Value of the sFlt-1:PlGF
Ratio in Women with Suspected Preeclampsia, 374, 34–42. Copyright © 2016 Massachusetts Medical Society. Reprinted
with permission from Massachusetts Medical Society).
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To rule out preeclampsia within 1 week, the negative-predictive value (NPV) of the selected
level of ≤38 was 99.3%, with a sensitivity and specificity of 80.0 and 78.3%, respectively. To
rule in preeclampsia within 4 weeks, an Elecsys® sFlt-1/PlGF ratio of >38 had a positive-
predictive value (PPV) of 36.7%, with a sensitivity and specificity of 66.2 and 83.1%, respec‐
tively. This PPV is high compared with other predictive tools that have historically been
employed: standard clinical and laboratory information (e.g., proteinuria and BP measure‐
ments) have PPVs of 20–26% in detecting preeclampsia-related adverse outcomes [179–181].
An Elecsys® sFlt-1/PlGF ratio of ≤38 was also predictive of the absence of fetal adverse outcomes
within 1 week (NPV of 99.3% in the validation cohort); a ratio of >38 was associated with a
PPV of 47.5% for these outcomes at 4 weeks. The sFlt-1/PlGF ratio is also CE-IVD approved
for use as an aid in short-term prediction of preeclampsia in pregnant women with suspicion
of preeclampsia in conjunction with other diagnostic and clinical information.
6.9. Tailoring preeclampsia health care using the sFlt-1/PlGF ratio
The Elecsys® sFlt-1/PlGF ratio has only recently been validated for the prediction of pree‐
clampsia, and so its value in tailoring the management of preeclampsia in clinical practice
remains to be fully seen. The use of the sFlt-1/PlGF ratio for the short-term prediction of
preeclampsia in women with suspected preeclampsia could guide PHC and ensure that the
right patients are monitored or referred, and receive appropriate interventions. The ability to
rule out preeclampsia could, in theory, prevent the unnecessary hospitalization with economic
benefits for health-care providers, although further analyses are needed to establish this [182].
Studies are currently underway to assess the value of the sFlt-1/PlGF ratio in clinical practice.
The Preeclampsia Open Study (PreOS), for example, aims to establish whether knowledge of
the Elecsys® sFlt-1/PlGF ratio influences a physician’s decision making, by assessing intended
procedures before and after knowledge of the sFlt-1/PlGF ratio [183].
The utilization of the sFlt-1/PlGF ratio could be used to guide future treatment options. A pilot
study examined the safety and efficacy of therapeutic apheresis to remove circulating sFlt-1
in 11 pregnant women (20–38 years of age) with very early-onset preeclampsia. In this study,
apheresis reduced the circulating levels of sFlt-1 by 18% (a range of 7–28%). In women who
received a single treatment or multiple treatments of apheresis, pregnancy continued for a
further 8 days (range 2–11 days) and 15 days (range 11–21 days), respectively. In control
patients with preeclampsia (n = 22), pregnancy continued for a further 3 days (range 0–14 days).
No adverse effects of apheresis were observed in the infants [184]. Further trials are needed to
confirm these results; if successful, knowledge of the sFlt-1/PlGF ratio could be used to help
identify women who are most likely to benefit from such therapy.
6.10. Current recommendations for the use of preeclampsia biomarkers
In the UK, the National Institute for Health and Care Excellence (NICE) has recommended (as
of May 2016) the use of the Elecsys® immunoassay sFlt-1/PlGF ratio and Triage® PlGF test, in
combination with standard clinical assessment, to help rule out preeclampsia in women of
week 20 + 0 days to 34 weeks + 6 days gestation [174]. NICE suggest that further research is
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needed before the DELFIA® Xpress PlGF 1-2-3 test and BRAHMS sFlt-1 KryptorTM/BRAHMS
PlGF plus KryptorTM PE ratio can be recommended [174]. In Germany, the sFlt-1/PlGF ratio
has been incorporated into guidelines on preeclampsia as a diagnostic aid [185].
A consensus statement has recently been published, providing guidance on the use of the
Elecsys® immunoassay sFlt-1/PlGF ratio in women with singleton pregnancies who have signs
or symptoms of preeclampsia [154]. According to this guidance, if the ratio is <38, the patient
is unlikely to develop preeclampsia within 1 week and further management is at the clinician’s
discretion. If the ratio is >85 (in women of early gestation) or >110 (in women of late gestation),
preeclampsia or placental dysfunction is present, and the patient should be managed accord‐
ing to local guidelines (severely elevated ratios may indicate the need for fetal lung maturation
and delivery). If the sFlt-1/PlGF ratio is 38–85 (early gestation) or 38–110 (late gestation), a
diagnosis of preeclampsia cannot be definitively made, but the patient is highly likely to
develop the condition within 4 weeks. If this occurs in early gestation, a follow-up test within
1–2 weeks should be considered. If this occurs during late gestation, the health-care team
should consider lowering the threshold for the induction of delivery.
6.11. Medical value
The sFlt-1/PlGF ratio is a typical example for a medical value test, consisting of two established
markers. The medical value component in this case has been established by analyzing how
this ratio can contribute to a better patient management. Without this analysis, the clinical
value of both markers alone would be somewhat lower. Therefore, the “value” term arises
around patients and payers simultaneously describing a framework for performance im‐
provement in health care [186]. The medical value component consists of two pivotal factors
and follows a stringent definition:
i. A medical value test must show improved patient outcomes, derived through
algorithms, validated in clinical utility studies addressing an unmet medical need.
ii. Deliver actionable and medically relevant information enabling support and guid‐
ance in decision making.
Ultimately, such tests may justify a change of the current disease management and thus can
help to reduce direct and indirect health-care costs. Medical value is added, when, for example,
a test allows patient stratification into responders/non-responders for a given medical
treatment or allows a more efficient/more effective allocation of patients to a certain treatment
or disease management [187].
7. Closing remarks (summary)
Owing to a complex interaction between genes and proteins in combination with environ‐
mental factors that lead to hypertension [188, 189], and despite an increasing body of knowl‐
edge regarding genes involved in the pathophysiology of essential hypertension, the
commercialization of PHC biomarkers in clinical practice is still at an early stage.
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Technologies such as NGS together with computational methods allow us to analyze rela‐
tionships between genetic and epigenetic factors influencing essential hypertension [188]. Up
to now, these technologies have been used mainly for research [79], but in the future such
technologies could be used to optimize treatment and primary prevention by combining
comprehensive and detailed PHC. Knowing an individual’s sequencing data might help to
assess the risk for hypertension, while the use of a biosensor to continuously monitor changes
in BP would allow physicians to make the treatment decisions at the earliest time point possible
and hence avoid organ damage [94]. Arrays of genetic markers, along with clinical factors and/
or other biomarkers, could be utilized for the development of mathematical algorithms
predicting BP response to a given antihypertensive drug, similar to that used for warfarin
pharmacogenetic dosing [190]. “Risk scores” for genetic markers may guide the prediction of
the “best drug” avoiding long-term cardiovascular complications (e.g., stroke, atrial fibrilla‐
tion, etc.).
Contemporary guidelines for the treatment of hypertension mention the potential of pharma‐
cogenomics. An increased uptake of the use of personalized treatments is expected in upcom‐
ing years, although more studies are needed to generate a body of clinical evidence before
genetic testing can be fully introduced in the treatment of cardiovascular diseases. For the first
time, a new scientific statement from the ACC, AHA, and ASH on the treatment of hyperten‐
sion in patients with coronary artery disease [191] refers to genetic-susceptibility variants for
atherosclerotic disease and/or BP response to antihypertensive treatment. The guidelines
discuss that the determination of genetic variants may be of some use for selecting appropriate
antihypertensive agents to reduce both BP and the risk for coronary artery disease [192]. Thus,
with the emergence of pharmacogenetics and other potential “-omics” biomarkers to guide
antihypertensive treatment, guidelines are needed for biomarker qualification and clinical
validation and to allow translation into clinical tools for clinical application.
The sFlt-1/PlGF ratio is a predictive and diagnostic tool in maternal care that could support
the shift toward PHC in preeclampsia management. Measurement of this biomarker ratio in
women with suspected preeclampsia can aid physician decision making, and help ensure that
the right women receive the monitoring and specialist perinatal care that they require, while
avoiding unnecessary hospitalizations.
PHC and pharmacogenomic testing has the potential to predict the response to antihyperten‐
sive therapy and to adequately select the appropriate dose that may ensure maximal efficacy,
especially in patients with end-stage hypertensive disease, malignant hypertension, or
treatment-refractory hypertension. This concept reduces the utilization of cost-intensive drugs
in non-responders and avoids costs related to the treatment of side effects or due to the
withdrawal of drugs [193]. While physicians must be trained in the handling and interpretation
of test results, patients and payers must also be educated on the benefits and limitations of
PHC. However, broad acceptance of such tests can only be obtained with a trained clinical
workforce and compelling economic evidence for payers that pretreatment testing is efficient.
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